Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also looks ripe to announce a stock split. Eli Lilly's shares look attractive ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug candidate, teeing the drugmaker up to target people taking Novo Nordisk’s ...

Orforglipron maintains weight loss after switching from injectable GLP-1 drugs Lilly and Novo Nordisk await U.S. regulatory approvals for weight-loss pills FDA may expedite review of Lilly's ...

Eli Lilly is positioned for a secular growth trajectory, leveraging its duopoly in diabetes and obesity therapies while investing heavily in pipeline diversification. LLY faces intensifying ...

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market today and has a pipeline of promising candidates to potentially reinforce its ...

Eli Lilly's recent long streak of correction for nine trading days calls for a look at the stock even as it has stabilised now. It's explained by stretched valuations and also the lowering of prices ...

Dec 17 (Reuters) - Eli Lilly (LLY.N), opens new tab is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada, the Globe and Mail reported on ...

Last night’s IT: Welcome to Derry Season 1 finale revealed that the HBO show has been even more intrinsically linked to Andy Muschietti‘s It and IT: Chapter Two than we initially thought. **Spoilers ...